Management

Luc Tanguay, M.Sc., CFA
President and Chief Executive Officer
Luc Tanguay has been active in the biotechnology industry for over 20 years. As a member of senior management at Theratechnologies since 1996, he has contributed to the Company’s growth by facilitating access to public and private capital funding. A member of the Board of Directors since 1993, he has held various management posts since joining the Company. Prior to joining Theratechnologies, Mr. Tanguay had a successful career in investment banking at Lévesque Beaubien (now National Bank Financial) where he helped several organizations establish themselves as public companies.
   
Marie-Noël Colussi, CPA, CA
Vice President, Finance
Marie-Noël Colussi is a graduate of Université du Québec à Montréal in business administration. Prior to joining Theratechnologies, Ms. Colussi worked for eight years with KPMG, a major accounting firm. Ms. Colussi has acquired sound experience in accounting, auditing, control and taxation, particularly in R&D. She joined Theratechnologies in March 1997, and prior to her appointment as Vice President, Finance in February 2002, she successively held the positions of Director, Accounting and Internal Control as well as Controller.
   
Philippe Dubuc, MBA
Senior Vice President and Chief Financial Officer
Mr. Dubuc brings more than 25 years of experience in investment banking in the healthcare sector and in management. He started his career as a management consultant at Groupe Secor, a well-known Quebec-based consulting firm which is now part of KPMG. He then served as Managing Director, Investment Banking at National Bank Financial. In this role, he headed the healthcare group and was involved in numerous financing and M&A transactions. He later founded a manufacturing company which he sold after seven years of successful operations. Mr. Dubuc holds a M.B.A. from McGill University and a B.Comm. from Concordia University. Mr. Dubuc joined Theratechnologies in February 2016.
   
Lyne Fortin, MBA, B.Pharm.
Senior Vice President and Chief Commercial Officer
Mrs. Fortin has over 27 years of experience in the commercialization of pharmaceutical products for human health. She has been in executive level positions at Merck Canada for 13 years until 2011. In these roles she was responsible for Marketing and Sales of product portfolios in diverse therapeutic areas. She also managed all the commercial support functions which included marketing and sales research, sales training, sales operations, manufacturing planning, Office of Compliance, Sigma and change management. From 2005 to 2009, she was appointed to the Merck Marketing Committee for Europe, Middle-East, Africa and Canada to advance commercial practices and became a member of the Board of Directors of Merck Canada in 2007 until 2011. From 2011 to 2013, she acted as consultant to the biopharmaceutical industry advising clients on commercial matters. She was appointed Chief Commercial Officer of our Corporation in December 2013.
 
Mrs. Fortin graduated from University of Montréal with a Certificate in Chemistry in 1978 and a Bachelor degree in Pharmacy in 1982. She obtained a MBA from Concordia University in 1984 and is a Member of the Order of Pharmacists of Québec since 1983.
   
Jocelyn Lafond, LL.B., LL.M.
Vice President, Legal Affairs, and Corporate Secretary
Mr. Lafond has 20 years of experience in the fields of corporate and securities laws. Mr. Lafond holds a law degree from Université Laval and a Masters Degree in Law from the University of Toronto. He has been a member of the Barreau du Québec since 1992. Prior to joining Theratechnologies, Mr. Lafond was a partner with the international law firm of Fasken Martineau DuMoulin, LLP.
   
Christian Marsolais, Ph. D.
Senior Vice President, Chief Medical Officer
Dr. Christian Marsolais has over 15 years of experience in clinical research for large pharmaceutical companies, such as Sandoz Canada and BioChem Therapeutics. Before joining Theratechnologies in 2007, Dr. Marsolais held various positions at Pfizer Global Pharmaceuticals, where he was appointed Director of Medical Affairs, Therapeutic Areas, in 2004. In this position, Dr. Marsolais was responsible for the clinical program and the development of scientific initiatives, as well as the integration of the Scientific Affairs and Clinical Research for the Oncology and HIV Franchise. Dr. Marsolais holds a Ph.D. in biochemistry from the Université de Montréal.